HomeInsightsStock Comparison

Eris Lifesciences Ltd vs Themis Medicare Ltd Stock Comparison

Eris Lifesciences Ltd vs Themis Medicare Ltd Stock Comparison

Last Updated on: May 14, 2025

Key Highlights

  • The Latest Trading Price of ERIS Lifesciences Ltd is ₹ 1476 as of 14 May 11:21.
  • The P/E Ratio of ERIS Lifesciences Ltd changed from 16.9 on March 2020 to 29.2 on March 2024 . This represents a CAGR of 11.56% over 5 yearsThe P/E Ratio of Themis Medicare Ltd changed from 8.9 on March 2020 to 46.3 on March 2024 . This represents a CAGR of 39.07% over 5 years.
  • The Market Cap of ERIS Lifesciences Ltd changed from ₹ 5003 crore on March 2020 to ₹ 11442 crore on March 2024 . This represents a CAGR of 17.99% over 5 yearsThe Market Cap of Themis Medicare Ltd changed from ₹ 220.51 crore on March 2020 to ₹ 2015 crore on March 2024 . This represents a CAGR of 55.67% over 5 years.
  • The revenue of ERIS Lifesciences Ltd for the Dec '24 is ₹ 731.67 crore as compare to the Sep '24 revenue of ₹ 745.72 crore. This represent the decline of -1.88% The revenue of Themis Medicare Ltd for the Dec '24 is ₹ 94.83 crore as compare to the Sep '24 revenue of ₹ 122.57 crore. This represent the decline of -22.63%.
  • The ebitda of ERIS Lifesciences Ltd for the Dec '24 is ₹ 254.53 crore as compare to the Sep '24 ebitda of ₹ 269.06 crore. This represent the decline of -5.4% The ebitda of Themis Medicare Ltd for the Dec '24 is ₹ 6.99 crore as compare to the Sep '24 ebitda of ₹ 22.69 crore. This represent the decline of -69.19%.
  • The net profit of ERIS Lifesciences Ltd changed from ₹ 93.65 crore to ₹ 86.93 crore over 7 quarters. This represents a CAGR of -4.17% The net profit of Themis Medicare Ltd changed from ₹ 18.19 crore to ₹ 0.52 crore over 7 quarters. This represents a CAGR of -86.88% .
  • The Dividend Payout of ERIS Lifesciences Ltd changed from 13.76 % on March 2020 to 0 % on March 2024 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Themis Medicare Ltd changed from 10.11 % on March 2020 to 18.59 % on March 2024 . This represents a CAGR of 12.96% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About ERIS Lifesciences Ltd

  • Eris Lifesciences Limited was incorporated on January 25, 2007.
  • Subsequently, the name of the company was changed to 'Eris Lifesciences Private Limited' on February 9, 2007.
  • Further, the Company was converted into a Public Limited cCompany and the name was changed to 'Eris Lifesciences Limited' on February 2, 2017.
  • The Company has a manufacturing plant in Guwahati, Assam and is presently engaged in manufacturing and marketing of pharmaceutical products.
  • It has presence in high growth chronic, sub chronic and acute therapeutic areas that require high intervention of specialist and super specialist doctors.

About Themis Medicare Ltd

  • Themis Medicare Limited was formerly incorporated as 'Themis Chemicals Limited' in 1969.
  • The Company was originally promoted by Chemosyn and Medimpex but was taken over by a Group consisting of Shantibhai D Patel and K T Lakdawala who also have interests in Andhra Synthetics and Antibiotics, which was merged with Artemis Pharmaceuticals in April, 1993.
  • Thereafter, the name of the Company was changed to Themis Medicare Limited in 2001.
  • The Group is principally engaged in the activities pertaining to manufacturing of pharmaceutical products, especially in Formulation and API activity. In Mar.'95, the company came out with a public issue equity shares (premium : Rs 110) to finance the expansion-cum-modernisation of its synthetic bulk drug plant at Vapi, the setting up of a formulation unit at Lilora, Baroda as backward integration and to augment long-term working capital.

ERIS Lifesciences Ltd News Hub

News

Eris Lifesciences allots 33,287 equity shares under ESOP

Eris Lifesciences has allotted 33,287 equity shares under ESOP on 06 March 2025. The paid-...

Read more

06 Mar 2025 13:17

News

Eris Lifesciences avails credit facility of Rs 1,000 cr

Eris Lifesciences has availed credit facilities amounting to Rs 1000 crore from Kotak Mahi...

Read more

21 Feb 2025 09:22

News

Board of ERIS Lifesciences recommends Interim Dividend

ERIS Lifesciences announced that the Board of Directors of the Company at its meeting held...

Read more

07 Feb 2025 16:36

News

ERIS Lifesciences schedules board meeting

ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 7 Februa...

Read more

05 Feb 2025 14:58

News

ERIS Lifesciences to hold board meeting

ERIS Lifesciences will hold a meeting of the Board of Directors of the Company on 4 Februa...

Read more

29 Jan 2025 15:17

News

Board of Eris Lifesciences approves acquisition of 30% stake in Levim Lifetech

The Board of Eris Lifesciences at its meeting held on 25 October 2024 has approved the exe...

Read more

25 Oct 2024 18:47

Themis Medicare Ltd News Hub

News

Themis Medicare to discuss results

Themis Medicare will hold a meeting of the Board of Directors of the Company on 14 Februar...

Read more

11 Feb 2025 10:53

News

Themis Medicare to discuss results

Themis Medicare will hold a meeting of the Board of Directors of the Company on 25 October...

Read more

19 Oct 2024 10:22

News

Themis Medicare to hold board meeting

Themis Medicare will hold a meeting of the Board of Directors of the Company on 26 July 20...

Read more

17 Jul 2024 09:49

News

Board of Themis Medicare recommends final dividend

Themis Medicare announced that the Board of Directors of the Company at its meeting held o...

Read more

15 May 2024 10:44

News

Themis Medicare schedules AGM

Themis Medicare announced that the 54th Annual General Meeting(AGM) of the company will be...

Read more

15 May 2024 10:44

News

Themis Medicare announces board meeting date

Themis Medicare will hold a meeting of the Board of Directors of the Company on 14 May 202...

Read more

04 May 2024 10:14

SWOT Analysis Of ERIS Lifesciences Ltd

Strength

4

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Themis Medicare Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

BlinkX Score for ERIS Lifesciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Themis Medicare Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of ERIS Lifesciences Ltd and Themis Medicare Ltd

Which company has a larger market capitalization, ERIS Lifesciences Ltd or Themis Medicare Ltd?

Market cap of ERIS Lifesciences Ltd is 19,736 Cr while Market cap of Themis Medicare Ltd is 1,215 Cr

What are the key factors driving the stock performance of ERIS Lifesciences Ltd and Themis Medicare Ltd?

The stock performance of ERIS Lifesciences Ltd and Themis Medicare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for ERIS Lifesciences Ltd and Themis Medicare Ltd?

As of May 14, 2025, the ERIS Lifesciences Ltd stock price is INR ₹1449.25. On the other hand, Themis Medicare Ltd stock price is INR ₹132.05.

How do dividend payouts of ERIS Lifesciences Ltd and Themis Medicare Ltd compare?

To compare the dividend payouts of ERIS Lifesciences Ltd and Themis Medicare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions